Eli Lilly’s $2.9 Billion Merida Deal Expands Its Immunology Push

Lilly Adds Another Platform Beyond Obesity and Diabetes

Eli Lilly (LLY) agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, continuing a broad dealmaking push aimed at expanding its drug pipeline across additional therapeutic areas.

The acquisition gives Lilly Merida's lead candidate, MER511, which is in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier programs targeting allergic and other immune-mediated conditions. The transaction is expected to close in the fourth quarter of 2026, subject to customary conditions and regulatory approvals.

Key Points

• Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash, adding an immunology platform focused on selectively removing disease-causing antibodies.
• Merida's lead candidate, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease, while additional programs target allergic and other immune-mediated conditions.
• LLY stock traded lower despite the acquisition and encouraging Taltz-Zepbound combination data, reflecting the early development stage of Merida's pipeline and limited near-term financial visibility.

Merida Adds a Precision-Immunology Platform to Lilly’s Pipeline

Merida Biosciences is developing engineered Fc-based biologics designed to bind to and selectively clear pathogenic antibodies, which are antibodies involved in causing disease. The approach uses the body's natural mechanisms for clearing antibody complexes while also targeting the B cells producing those antibodies.

The intended advantage is greater precision: removing harmful antibodies while preserving protective immune function rather than broadly suppressing the immune system. That potential, however, remains subject to clinical validation.

MER511 is Merida's most advanced program. The drug is being evaluated in the Phase 1 NEXUS study for Graves' disease, with thyroid eye disease representing an additional potential application because both conditions involve antibodies targeting the thyroid-stimulating hormone receptor.

Initial data showed substantial reductions in thyroid-stimulating antibodies associated with those conditions, along with a favorable early safety profile.

Merida's pipeline extends beyond MER511. The company is developing MER769 for IgE-mediated allergic diseases including food allergy, asthma, atopic dermatitis and chronic spontaneous urticaria. It also has an IND-enabling program targeting primary membranous nephropathy and other earlier-stage immune-related programs.

The transaction includes an upfront cash payment and additional milestone payments, although Lilly did not disclose how the maximum $2.875 billion consideration is divided between those components.

That structure leaves limited visibility into Lilly's immediate cash commitment and how much of the acquisition price depends on future clinical and development milestones.

Why Did LLY Stock Move Lower on the Merida Deal?

Lilly shares declined more than 1% on Monday even as the company expanded its pipeline through another acquisition.

The muted reaction comes as MER511 remains in Phase 1 development, meaning the lead program is still at an early stage of clinical testing. The acquisition therefore adds potential future opportunities without establishing an immediate commercial contribution.

The structure of the transaction adds another element of uncertainty. Lilly disclosed a maximum value of $2.875 billion but did not disclose the upfront payment or the milestones required for Merida to receive the remaining consideration.

The Merida agreement also follows a significant increase in Lilly's acquisition activity. If completed, it would represent the company's 13th acquisition of 2026.

Immunology has become one part of that expansion. Earlier this year, Lilly agreed to acquire Orna Therapeutics, which develops therapies for B-cell-driven autoimmune diseases, for $2.4 billion in cash.

Other acquisitions have broadened Lilly's pipeline across oncology and additional therapeutic categories. The company acquired Kelonia Therapeutics and Ajax Therapeutics, expanding its blood cancer portfolio, while its $7.8 billion acquisition of Centessa Pharmaceuticals added neurological and sleep-wake disorder treatments, including programs targeting narcolepsy.

The strategy comes as Lilly's Mounjaro and Zepbound franchises continue to represent a substantial portion of the company's growth. Mounjaro generated $18.6 billion of first-half 2026 sales, up 106% year over year, while Zepbound generated $9.1 billion, up 60%. Lilly's overall first-half revenue increased 51%.

The Merida transaction extends Lilly's business-development activity into another potential growth platform outside its leading diabetes and obesity products.

Taltz and Zepbound Data Connect Metabolic and Immunology Treatments

Alongside the Merida announcement, Lilly reported 52-week results from two Phase 3b trials evaluating Taltz together with Zepbound in adults with psoriasis or psoriatic arthritis and obesity.

Among patients with psoriasis, 30.6% receiving Taltz plus Zepbound achieved both complete skin clearance and at least 10% weight loss after 52 weeks. That compared with 4.4% among patients receiving Taltz alone.

For patients with psoriatic arthritis, 39.2% receiving the combination achieved at least a 50% improvement in disease activity together with at least 10% weight loss. The corresponding figure for Taltz alone was 1.7%.

Disease-specific outcomes also favored the combination, while additional improvements were reported in body mass index, blood pressure, blood sugar, cholesterol and systemic inflammation. Adverse events were generally mild to moderate and consistent with the established safety profiles of the two medicines, with no new safety concerns reported.

The findings nevertheless come with important qualifications. The Week 52 analyses were prespecified exploratory objectives without multiplicity control, and the open-label studies have not yet been published in a peer-reviewed journal.

Lilly plans to present detailed results at future medical meetings.

Together, the Merida acquisition and the Taltz-Zepbound results place immunology and metabolic disease within the same broader company news story. The acquisition adds an early-stage platform targeting disease-causing antibodies, while the clinical trial results evaluate Lilly's existing obesity and immunology treatments together.

What It Means for Investors

The immediate LLY stock reaction highlights the difference between expanding a drug pipeline and adding a near-term commercial catalyst.

Merida gives Lilly access to a technology platform with potential applications across multiple antibody-driven diseases rather than a single drug candidate. But its most advanced program remains in Phase 1, and its other programs are even earlier in development.

That makes clinical progress central to assessing the transaction. For MER511, the relevant developments include its safety profile, the durability of reductions in harmful antibodies and advancement beyond early-stage testing. Merida's additional programs will also need to progress into human trials before their clinical potential becomes clearer.

The acquisition is also part of a larger diversification effort. Lilly's diabetes and obesity franchises are generating substantial growth, while the company has continued adding programs across immunology, oncology, neurological disorders and other therapeutic areas through acquisitions.

Competition in obesity remains another part of the backdrop. Novo Nordisk (NVO) is seeking U.S. approval for CagriSema and continues developing higher-dose versions after the drug failed to demonstrate non-inferiority to Zepbound in a Phase 3 head-to-head study. Structure Therapeutics (GPCR) and Viking Therapeutics (VKTX) are also advancing obesity treatments.

For Lilly, the Merida deal therefore adds another early-stage platform while the company's existing metabolic franchise continues to play a major role in its financial performance.

The Taltz-Zepbound results provide a separate development to watch. The 52-week data favored combination therapy across the reported measures, but the analyses were exploratory and no regulatory strategy for the combination was disclosed.

Conclusion

Eli Lilly's agreement to acquire Merida Biosciences for up to $2.875 billion extends an active acquisition strategy aimed at building additional sources of growth beyond its dominant obesity and diabetes franchises.

The strategic centerpiece is MER511, an early-stage treatment designed to selectively remove disease-causing antibodies in Graves' disease and thyroid eye disease. Merida's broader pipeline could extend the same approach into allergic and other immune-mediated diseases.

At the same time, Lilly's new Taltz-Zepbound data connect its metabolic and immunology businesses more directly, with the combination producing stronger reported 52-week outcomes than Taltz alone in patients with psoriasis or psoriatic arthritis and obesity.

LLY shares nevertheless moved lower following the announcements. Merida's pipeline remains early in development, the acquisition's upfront payment has not been disclosed, and the 52-week Taltz-Zepbound analyses remain exploratory.

The next developments will center on the expected fourth-quarter closing of the Merida transaction, further clinical progress for MER511 and Lilly's additional immunology programs, and more detailed results from the Taltz-Zepbound studies.

FAQs

How much is Eli Lilly paying for Merida Biosciences?

Eli Lilly agreed to acquire Merida Biosciences for up to $2.875 billion in cash. The consideration includes an upfront payment and additional milestone payments, although the amounts assigned to each component were not disclosed.

What does Merida Biosciences add to Eli Lilly?

Merida adds a precision-immunology platform designed to selectively remove disease-causing antibodies while preserving protective immune function. Its pipeline includes programs targeting autoimmune, allergic and other immune-mediated diseases.

What is MER511?

MER511 is Merida Biosciences' lead drug candidate. It is being evaluated in the Phase 1 NEXUS study for Graves' disease, with thyroid eye disease representing an additional potential opportunity. Initial data showed substantial reductions in thyroid-stimulating antibodies and a favorable early safety profile.

What did the Taltz and Zepbound trials show?

After 52 weeks, 30.6% of psoriasis patients receiving Taltz plus Zepbound achieved complete skin clearance and at least 10% weight loss, compared with 4.4% receiving Taltz alone. Among psoriatic arthritis patients, the corresponding combined disease improvement and weight-loss measure was achieved by 39.2% versus 1.7%.

When is Lilly’s acquisition of Merida expected to close?

The Merida Biosciences acquisition is expected to close in the fourth quarter of 2026, subject to customary closing conditions and regulatory approvals.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Go Beyond the Market Brief with Market Edge

Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass. Try Market Edge for $19 your first month →

Explore Research with Stock Investor

Stock Investor is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions.

Explore Active Trading & Income Strategies

Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities.

For options-focused traders, Essential Option Income provides a structured approach to options income strategies, while Pro Option Trader offers a broader range of options strategies and trade opportunities.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.